<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04234724</url>
  </required_header>
  <id_info>
    <org_study_id>833684</org_study_id>
    <secondary_id>R01HL148769</secondary_id>
    <nct_id>NCT04234724</nct_id>
  </id_info>
  <brief_title>Physiological Effects of ANGPTL3 Variants in Humans</brief_title>
  <official_title>Physiological Effects of ANGPTL3 Variants in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the role of ANGPTL3, on lipid metabolism. To explore the role of this protein on&#xD;
      glucose metabolism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oral fast tolerance test, lipoprotein kinetics and a glucose tolerance test to evaluate the&#xD;
      role of ANGPTL3, on lipid metabolism and to explore the role of this protein on glucose&#xD;
      metabolism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The role of ANGPTL3 on lipid metabolism.</measure>
    <time_frame>through study completion, an average of 13 weeks</time_frame>
    <description>Assessing ApoB-containing lipoprotein fractional catabolic rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The role of this protein on glucose metabolism.</measure>
    <time_frame>through study completion, an average of 13 weeks</time_frame>
    <description>Looking for glucose area under the curve following Oral Glucose Tolerance Test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The role of ANPTL3 on fatty acids</measure>
    <time_frame>through study completion, an average of 13 weeks</time_frame>
    <description>Looking for fatty acids area under the curve following Oral Fat Tolerance Test</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hypocholesterolemia</condition>
  <arm_group>
    <arm_group_label>Variant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers with known ANGPTL3 variants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-variant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy volunteers with no ANGPTL3 variants</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Kinetics test, oral fat tolerance test, and an oral glucose tolerance test.</intervention_name>
    <description>Subjects will participate in a kinetics test, oral fat tolerance test, and an oral glucose tolerance test.</description>
    <arm_group_label>Non-variant</arm_group_label>
    <arm_group_label>Variant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects aged 18 or older meeting at least one of the following criteria&#xD;
&#xD;
               1. Carrying genetic variants in the gene encoding for ANGPTL3,&#xD;
&#xD;
               2. Unaffected controls matched for age, race, gender,&#xD;
&#xD;
               3. Willing to follow study procedures&#xD;
&#xD;
               4. Able to provide inform consent&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
          -  Any medical or psychological conditions that, in the opinion of the investigator,&#xD;
             would compromise the subject's safety or successful participation in the study, or&#xD;
             confound the study data&#xD;
&#xD;
          -  Taking any medication that, in the opinion of the investigator, would compromise the&#xD;
             subject's safety or successful participation in the study, or confound the study data&#xD;
&#xD;
          -  Women that are pregnant or nursing&#xD;
&#xD;
          -  History of liver disease or abnormal liver function tests (&gt;2x upper limit of normal)&#xD;
&#xD;
          -  History of kidney disease or chronic renal insufficiency (eGFR &lt;60 mL/min/1.73 m2)&#xD;
&#xD;
          -  Uncontrolled hypertension (&gt;160/100 mmHg)&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
&#xD;
          -  Anemia (hemoglobin &lt;11.0 mg/dL) History of a non-skin malignancy within the previous 5&#xD;
             years Major surgery within the past 3 months&#xD;
&#xD;
          -  History of any organ transplant&#xD;
&#xD;
          -  History of alcohol or drug abuse&#xD;
&#xD;
          -  Participation in clinical trials assessing the efficacy and safety of drugs affecting&#xD;
             lipid metabolism within the past 6 weeks (or longer depending on the known half-life&#xD;
             of the drug) that, in the opinion of the investigator, would compromise the subject's&#xD;
             safety or successful participation in the study, or confound the study data&#xD;
&#xD;
          -  Inability to comply to study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Cuchel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marina Cuchel, MD, PhD</last_name>
    <phone>215-662-7188</phone>
    <email>mcuchel@pennmedicine.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Vincent, MRA</last_name>
      <phone>215-615-5448</phone>
    </contact>
    <investigator>
      <last_name>Marina Cuchel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 21, 2020</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Angiopoietin-like protein 3 deficiency</keyword>
  <keyword>Lipid Metabolism</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT04234724/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

